HD21 study for Adcetris® in the BrECADD regimen

The HD21 study is a randomized, multicenter, open-label phase 3 study involving 1500 patients with newly diagnosed, advanced-stage, cHL from 233 study centers in 9 countries. The study compared BrECADD vs. eBEACOPP. [1]


Key results:

  • According to a meta-analysis, BrECADD achieved the highest and most sustained 3-year PFS rate in patients <60 years. [2]
  • In the 4-year follow-up, a 34% reduction in the risk of progression or death was observed under BrECADD compared to eBEACOPP (HR: 0.66; 95% CI: 0.45–0.97; p=0.035) [1]
  • The overall survival rate was comparable between BrECADD (98.6%) and eBEACOPP (98.2%) [1]
  • Patients in the BrECADD arm had a 28% lower relative risk of treatment-related morbidity compared to patients in the eBEACOPP arm (RR: 0.72; 95% CI: 0.65–0.80). [1]
  • The incidence of severe acute hematologic toxicities was reduced with BrECADD vs. eBEACOPP (31% vs. 52%). [1]
  • Improved gonadal function recovery with BrECADD correlated with higher numbers of childbirth. [1]
  • With BrECADD, the quality of life during the first two years of follow-up was significantly improved compared to eBEACOPP.°, [3]
     

° First year: β=0.12, p=0.0041; second year: β=0.11, p=0.0225


BrECADD: brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone; cHL: classical Hodgkin lymphoma; eBEACOPP: escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone


Healthcare professionals may request a complete copy of the cited literature from the pharmaceutical company.


Adcetris® Information for healthcare professionals, www.swissmedicinfo-pro.ch 

C-APROM/CH/ADCE/0095_11/2025

References

  • 1. Borchmann P, et al. Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial. Lancet 2024;404(10450):341–352.

  • 2. Visentin A, et al. BRECADD: THE OPTIMAL TREATMENT FOR ADVANCED-STAGE HODGKIN LYMPHOMA — A METANALYSIS AND AN INDIRECT COMPARISON WITH INDIVIDUAL PATIENT DATA EXTRACTION. Oral presentation at EHA Congress 2025, 12–15 June 2025, Milan, Italy. Abstract: S227.

  • 3. Ferdinandus J, et al. Treatment effects of BrECADD on health-related quality of life: an analysis of patient reported outcomes in the randomized international phase III german Hodgkin study group HD21 trial. Poster P110 presented at EHA 2024, 13–16 June 2024, Madrid, Spain. https://library.ehaweb.org/eha/2024/ eha2024- congress/419187/justin.ferdinandus.treatment.effects.of.brecadd.on.health-related.quality.of.html (last accessed: September 2025).